北京大学学报(医学版) ›› 2021, Vol. 53 ›› Issue (2): 246-254. doi: 10.19723/j.issn.1671-167X.2021.02.003
廖栩鹤1,王荣福1,Δ(),刘萌1,Δ(),陈雪祺1,熊焰2,农琳2,殷雷1,张炳晔1,杜毓菁1
LIAO Xu-he1,WANG Rong-fu1,Δ(),LIU Meng1,Δ(),CHEN Xue-qi1,XIONG Yan2,NONG Lin2,YIN Lei1,ZHANG Bing-ye1,DU Yu-jing1
摘要:
目的: 评估18F-FDG PET/CT半定量参数、表皮生长因子受体(epidermal growth factor receptor,EGFR)和间变淋巴瘤激酶(anaplastic lymphoma kinase,ALK)基因突变状态对肺腺癌患者预后评估的价值。方法: 回顾性收集84名肺腺癌患者术前18F-FDG PET/CT半定量参数,EGFR及ALK基因突变检查结果。18F-FDG PET/CT半定量参数分别为:最大标准化摄取值(maximum standardized uptake value,SUVmax)、平均标准化摄取值(average of standardized uptake value,SUVmean)、肿瘤代谢体积(metabolic tumor volume,MTV)和总糖酵解量(total lesion glycolysis,TLG)。连续变量用ROC曲线分析法转为分类变量,生存分析采用Cox比例风险回归分析,生存曲线经Log-rank检验和Kaplan-Meier法获得。结果: 患者平均随访期31个月(24~58个月)。单因素分析显示,原发灶SUVmax、SUVmean、MTV及TLG与无进展生存期(progression-free survival,PFS)显著相关。多因素Cox比例风险回归分析显示,不论年龄、性别、合并症、EGFR或ALK基因突变与否及治疗情况,TLG(≥55.02,HR=4.965,95%CI:1.360~18.133)、TNM分期(Ⅲ/Ⅳ期,HR=7.811,95%CI:2.977~20.489)、胃泌素释放肽前体(pro-gastrin releasing peptide,proGRP)(≥45.65 ng/L,HR=4.070,95%CI:1.442~11.487)、组织多肽抗原(tissue polypeptide antigen,TPA)(≥68.20 U/L,HR=6.996,95%CI:1.458~33.574)、碱性磷酸酶(alkaline phosphatase,ALP)(≥82.50 IU/L,HR=4.160,95%CI:1.416~12.219)和活化部分凝血活酶时间比值(ratio of activated partial thromboplastin time,aPTTR)(≥1.16,HR=4.576,95%CI:1.913~10.946)为独立显著预后因素。EGFR(P=0.343)或ALK(P=0.608)基因突变状态均与PFS无显著相关。结论: 原发灶高水平18F-FDG PET/CT半定量参数(SUVmax、SUVmean、MTV和TLG)对肺腺癌患者具有不同程度的预后评估价值,TNM分期、proGRP、TPA、ALP和aPTTR均与PFS存在独立、显著关联,EGFR或ALK基因突变状态与PFS未见明确相关。
中图分类号:
[1] | Noone A, Howlader N, Krapcho M, et al. SEER cancer statistics review (CRS), 1975-2015[EB/OL]. (2018-09-10) [2018-09-10]. https://seer.cancer.gov/csr/1975_2015/. |
[2] |
Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress[J]. Chest, 2002,122(3):1037-1057.
doi: 10.1378/chest.122.3.1037 pmid: 12226051 |
[3] |
Sharma A, Mohan A, Bhalla AS, et al. Role of various metabolic parameters derived from baseline 18F-FDG PET/CT as prognostic markers in non-small cell lung cancer patients undergoing platinum-based chemotherapy[J]. Clin Nucl Med, 2018,43(1):e8-e17.
pmid: 29112011 |
[4] |
Salavati A, Duan F, Snyder BS, et al. Optimal FDG PET/CT volumetricparameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial[J]. Eur J Nucl Med Mol Imaging, 2017,44(12):1969-1983.
doi: 10.1007/s00259-017-3753-x pmid: 28689281 |
[5] |
Wang WT, Li Y, Ma J, et al. Serum carcinoembryonic antigen levels before initial treatment are associated with EGFR mutations and EML4-ALK fusion gene in lung adenocarcinoma patients[J]. Asian Pac J Cancer Prev, 2014,15(9):3927-3932.
doi: 10.7314/apjcp.2014.15.9.3927 pmid: 24935562 |
[6] |
Chung HW, Lee KY, Kim HJ, et al. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma[J]. J Cancer Res Clin Oncol, 2014,140(1):89-98.
doi: 10.1007/s00432-013-1545-7 pmid: 24194352 |
[7] |
Nisman B, Amir G, Lafair J, et al. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer[J]. Anticancer Res, 1999,19(4C):3549-3552.
pmid: 10629651 |
[8] |
Ma W, Wang M, Li X, et al. Quantitative 18F-FDG PET analysis in survival rate prediction of patients with non-small cell lung cancer[J]. Oncol Lett, 2018,16(4):4129-4136.
doi: 10.3892/ol.2018.9166 pmid: 30214552 |
[9] |
Melloni G, Gajate AM, Sestini S, et al. New positron emission tomography derived parameters as predictive factors for recurrence in resected stage Ⅰ non-small cell lung cancer[J]. Eur J Surg Oncol, 2013,39(11):1254-1261.
doi: 10.1016/j.ejso.2013.07.092 pmid: 23948705 |
[10] |
Hyun SH, Choi JY, Kim K, et al. Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection[J]. Ann Surg, 2013,257(2):364-370.
pmid: 22968069 |
[11] |
Kurtipek E, Cayci M, Duzgun N, et al. 18F-FDG PET/CT mean SUV and metabolic tumor volume for mean survival time in non-small cell lung cancer[J]. Clin Nucl Med, 2015,40(6):459-463.
doi: 10.1097/RLU.0000000000000740 pmid: 25742234 |
[12] |
Camidge DR, Kono SA, Lu X, et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed[J]. J Thorac Oncol, 2011,6(4):774-780.
pmid: 21336183 |
[13] |
Izar B, Sequist L, Lee M, et al. The impact of EGFR mutation status on outcomes in patients with resected stage Ⅰ non-small cell lung cancers[J]. Ann Thorac Surg, 2013,96(3):962-968.
pmid: 23932319 |
[14] |
Nisman B, Biran H, Ramu N, et al. The diagnostic and prognostic value of ProGRP in lung cancer[J]. Anticancer Res, 2009,29(11):4827-4832.
pmid: 20032442 |
[15] |
Cistaro A, Quartuccio N, Mojtahedi A, et al. Prediction of 2 years-survival in patients with stage Ⅰ and Ⅱ non-small cell lung cancer utilizing (18)F-FDG PET/CT SUV quantification[J]. Radiol Oncol, 2013,47(3):219-223.
pmid: 24133385 |
[16] |
Soussan M, Chouahnia K, Maisonobe JA, et al. Prognostic implications of volume-based measurements on FDG PET/CT in stage Ⅲ non-small-cell lung cancer after induction chemotherapy[J]. Eur J Nucl Med Mol Imaging, 2013,40(5):668-676.
pmid: 23306807 |
[17] | Liu J, Dong M, Sun X, et al. Prognosticvalue of 18F-FDG PET/CT in surgical non-small cell lung cancer: a meta-analysis[J]. PLoS One, 2016,11(1):e146195. |
[18] |
Ohtaka K, Hida Y, Kaga K, et al. Outcome analysis of 18F-fluorodeoxyglucose positron-emission tomography in patients with lung cancer after partial volume correction[J]. Anticancer Res, 2013,33(11):5193-5198.
pmid: 24222169 |
[19] |
Caicedo C, Garcia-Velloso MJ, Lozano MD, et al. Role of 18F-FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer[J]. Eur J Nucl Med Mol Imaging, 2014,41(11):2058-2065.
pmid: 24990403 |
[20] |
Liu A, Han A, Zhu H, et al. The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer[J]. Oncotarget, 2017,8(20):33736-33744.
pmid: 28422710 |
[21] | Li Q, Zhang J, Cheng W, et al. Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of positron emission tomography/computed tomography in patients with nasopharyngeal carcinoma: A systematic review and meta-analysis[J]. Medicine (Baltimore), 2017,96(37):e8084. |
[22] |
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009,361(10):947-957.
pmid: 19692680 |
[23] |
Koizumi T, Fukushima T, Gomi D, et al. Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer[J]. Med Oncol, 2017,34(10):169.
doi: 10.1007/s12032-017-1032-0 pmid: 28864950 |
[24] |
Foa P, Fornier M, Miceli R, et al. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer[J]. Anticancer Res, 1999,19(4C):3613-3618.
pmid: 10629660 |
[25] |
Alatas F, Alatas O, Metintas M, et al. Usefulness of bone mar-kers for detection of bone metastases in lung cancer patients[J]. Clin Biochem, 2002,35(4):293-296.
pmid: 12135691 |
[26] |
Qi Y, Fu J. Research on the coagulation function changes in non small cell lung cancer patients and analysis of their correlation with metastasis and survival[J]. J BUON, 2017,22(2):462-467.
pmid: 28534370 |
[27] | Ettinger DS, Wood DE, Aisner DL, et al. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: non-small cell lung cancer (2019V2)[EB/OL]. (2018-11-21) [2018-11-21]. https://www.nccn.org/professionals/physician_gls/default.aspx. |
[1] | 白杲琛,宋毅,金杰,虞巍,何志嵩. 多西他赛联合卡铂治疗转移性去势抵抗性前列腺癌的临床疗效[J]. 北京大学学报(医学版), 2021, 53(4): 686-691. |
[2] | 王迎春,黄永辉,常虹,姚炜,闫秀娥,李柯,张耀鹏,郑炜. 十二指肠乳头息肉良、恶性病变比较及活检准确性[J]. 北京大学学报(医学版), 2021, 53(1): 204-209. |
[3] | 鲍轶,莫娟芬. 同时性多原发肺腺癌组织编码转录因子ERG基因相同位点突变1例报告[J]. 北京大学学报(医学版), 2020, 52(5): 971-974. |
[4] | 徐涛,韩敬丽,姚伟娟. 雄激素剥夺治疗相关心血管疾病的机制与临床对策[J]. 北京大学学报(医学版), 2020, 52(4): 607-609. |
[5] | 李文卿,任思楣,龙星博,田雨青. 棕榈酰化蛋白质组学分析揭示前列腺癌细胞中雄激素促进代谢相关蛋白棕榈酰化修饰[J]. 北京大学学报(医学版), 2020, 52(2): 227-233. |
[6] | 孙奎霞,闫存玲,李志艳,刘平,张伟,何群. 前列腺特异性抗原同源异构体2及其衍生指标在预测前列腺癌病理分级中的价值[J]. 北京大学学报(医学版), 2020, 52(2): 234-239. |
[7] | 耿良,吕静,范敬. 肺瘤平膏联合环磷酰胺化疗对肺癌的抑瘤作用和酸性微环境的影响[J]. 北京大学学报(医学版), 2020, 52(2): 247-253. |
[8] | 梁学军,宫丽颖,周菲,周德敏,祝静静. 非天然氨基酸定点偶联抗人类表皮生长因子受体2-抗体偶联药物的药理学活性[J]. 北京大学学报(医学版), 2019, 51(5): 797-804. |
[9] | 王思源,王殊. 抗缪勒管激素用于戈舍瑞林在年轻乳腺癌患者化疗期间保护卵巢储备功能的评价[J]. 北京大学学报(医学版), 2019, 51(3): 536-541. |
[10] | 张宽根,周雨禾,邵雅昆,梅放,由江峰,刘北英,裴斐. 肿瘤转移抑制基因LASS2/TMSG1 S248A突变体通过增加ATP6V0C表达促进前列腺癌的侵袭[J]. 北京大学学报(医学版), 2019, 51(2): 210-220. |
[11] | 张春凤,刘云,陆敏,杜晓娟. hUTP14a在非小细胞肺癌组织中的表达[J]. 北京大学学报(医学版), 2019, 51(1): 145-150. |
[12] | 唐旭,赵卫红,宋琴琴,殷华奇,杜依青,盛正祚,王强,张晓威,李清,刘士军,徐涛. SOX10对前列腺癌细胞增殖及侵袭的影响[J]. 北京大学学报(医学版), 2018, 50(4): 602-606. |
[13] | 张晓东,刘德若. 肺腺癌新分类与表皮生长因子受体基因突变之间的关系[J]. 北京大学学报(医学版), 2018, 50(4): 640-644. |
[14] | 覃子健,毕海,马潞林,黄毅,张帆. 肠代膀胱内原发肠源性腺癌1例[J]. 北京大学学报(医学版), 2018, 50(4): 737-739. |
[15] | 孙海涛,杨瑞杰,江萍,姜伟娟,李金娜,孟娜,王俊杰. 乳腺癌保乳术后容积旋转调强和切线野调强放疗的剂量学比较[J]. 北京大学学报(医学版), 2018, 50(1): 188-192. |
|